Demircioglu Zeynep Gul, Aygun Nurcihan, Demircioglu Mahmut Kaan, Ozguven Banu Yilmaz, Uludag Mehmet
Department of General Surgery, Kars Harakani State Hospital, Kars, Turkey.
Department of General Surgery, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
Sisli Etfal Hastan Tip Bul. 2022 Mar 28;56(1):132-136. doi: 10.14744/SEMB.2022.36048. eCollection 2022.
In the present study, we investigated the effects of Vitamin D (vit D) deficiency on aggressiveness of papillary thyroid cancer (PTC).
Patients with PTC confirmed with pathological examination, whom were operated by a single surgeon between 2012 and 2017, were included in the study. The data of the patients were analyzed retrospectively. Cancers other than PTC, patients with hyperthyroidism and/or using antithyroid drugs were excluded from the study. The patients were classified as four quartiles according to serum Vit D levels; category 1 (<7.1 ng/mL), category 2 (7.2-11.8 ng/mL), category 3 (11.9-23.4 ng/mL) and category 4 (>23.5 ng/mL).
A total of 133 patients (103 female, 30 male) with mean age of 46.4±13.6 (17-82) years were included in the study. There was no significant difference between the categories in terms of preoperative Vit D values according to the evaluated tumor aggressiveness characteristics. It was determined that the presence of tumor with a size above 1 cm and T3/4 tumor were not affected by Vit D level. There was no significant difference between Vit D categories regarding the characteristics of aggressiveness such as multicentricity, lymphovascular invasion, central, and lateral metastases.
According to our results, serum Vit D levels are not associated with the aggressive tumor characteristics of PTC.
在本研究中，我们调查了维生素D（Vit D）缺乏对甲状腺乳头状癌（PTC）侵袭性的影响。
本研究纳入了2012年至2017年间由同一外科医生进行手术且经病理检查确诊为PTC的患者。对患者的数据进行回顾性分析。排除PTC以外的癌症、甲状腺功能亢进症患者和/或正在使用抗甲状腺药物的患者。根据血清Vit D水平将患者分为四个四分位数；第1组（<7.1 ng/mL）、第2组（7.2 - 11.8 ng/mL）、第3组（11.9 - 23.4 ng/mL）和第4组（>23.5 ng/mL）。
本研究共纳入133例患者（女性103例，男性30例），平均年龄为46.4±13.6（17 - 82）岁。根据评估的肿瘤侵袭性特征，各亚组术前Vit D值之间无显著差异。确定肿瘤大小大于1 cm和T3/4期肿瘤的存在不受Vit D水平影响。在多中心性、淋巴管侵犯、中央和侧方转移等侵袭性特征方面，Vit D亚组之间无显著差异。
根据我们的结果，血清Vit D水平与PTC的侵袭性肿瘤特征无关。
